Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion ...
The Allurion Balloon, a non-surgical gastric balloon for weight loss, has previously shown promise when used in tandem with GLP-1 agonists. A study published in Obesity Surgery revealed that ...
The Allurion Balloon, a non-surgical gastric balloon for weight loss, has previously shown promise when used in tandem with GLP-1 agonists. A study published in Obesity Surgery revealed that patients ...
In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion ...
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback